Thank you for downloading the Susanne Michen et. al. CIMT 2023 Poster
This scientific poster presented at CIMT 2023 investigates glioblastoma, a WHO grade IV glioma and the most common primary adult brain tumor, and the expression of elevated levels of HLA-E that block NK cells with expression of the inhibitory NKG2A receptor, aiming to establish a large-scale ex vivo expansion of functional NKG2C+ NK cells. Doing so from peripheral blood employing bottom-gas permeable membrane bioreactors (G-Rex) and using a recently developed PC-3 feeder cell line genetically engineered with IL-2, membrane-bound IL-15, as well as a first generation single chain trimeric HLA-E molecule.
Latest Insights
Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy
Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.
Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success
Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.
Advancing Immune Cell Therapies Through Efficient Cell Culture Techniques
In an expert roundtable discussion by Cell and Gene Therapy Insights, the potential of cell culture in immune cell therapies takes center stage, offering promising possibilities for the future of regenerative medicine.
Are you ready to scale?
Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.